Antigenics Cancer Drugs Clinical Pipeline Insight

Publish Date:- Mar-2016      No Of Pages (29)

Electronic Access - Single User License $500 Buy Now
CD-ROM Mail Delivery $800Buy Now
Hard Copy Mail Delivery $800 Buy Now
Electronic Access - Multi-User License $1000 Buy Now


“Antigenics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Antigenics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline and majority of them are in preclincal phase. There are 2 cancer drugs by Antigenics which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Antigenics-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.


“Antigenics - Cancer Drugs Clinical Pipeline Insight” offers in depth insight on ongoing clinical trials for the cancer drugs developed by Antigenics. This report highlights various clinical and non-clinical parameters involved in the development of cancer drugs in clinical pipeline. Currently there are “8” cancer drugs in clinical pipeline and majority of them are in preclincal phase. There are 2 cancer drugs by Antigenics which are commercially available in the market.

The report includes all the relevant information with respect to development of cancer drugs in the clinical pipeline. Report helps the reader in identifying various data and information points like Drug Class, Mechanism of Action, Granted Orphan Designation, Fast Track Development Status, Clinical Introduction, Drug Formulation/ Route, Owner/License, Multiple Development Phase of particular drug and Patent Information.

“Antigenics-Cancer Drugs Clinical Pipeline Insight” report is comprehensively researched and well drafted encyclopedia which helps to analyze and understand the various parameters involved in the clinical development of cancer drugs by the respective company. This research publication also helps in identifying the long term investment and partnering opportunity for the various stake holders of the pharmaceutical industry.

1. Antigenics

  1.1 Business Overview

  1.2 Antigenics Cancer Pipeline Overview

 

2. Antigenics Cancer Drugs in Research Phase

  2.1 CD66 Antigen Modulators – Agenus

  2.2 Antibody-Based Cancer Immunotherapies - Agenus/Merck

  2.3 Monoclonal Antibody Therapeutics – Agenus

 

3. Antigenics Cancer Drugs in Preclinical Phase

  3.1 Cancer Vaccines – Agenus

  3.2 Monoclonal Antibodies Mimicking T Cell Receptors – Agenus

 

4. Antigenics Cancer Drugs in Phase-I

  4.1 AGEN 1884

 

5. Antigenics Cancer Drugs in Phase-I/II

  5.1 INCAGN 1876

 

6. Antigenics Cancer Drugs in Phase-III

  6.1 Zastumotide

 

7. Marketed Cancer Drugs in Antigenics

  7.1 Vitespen (Oncophage)

  7.2 Mopidamol (Rapenton)

 

8. Discontinued in Cancer Drugs in Clinical Pipeline

  8.1 AR 623

  8.2 L-NDDP

  8.3 MJV 101


Figure 1-1: Antigenics Cancer Pipeline by Phase (%)

Figure 1-2: Antigenics Cancer Pipeline by Phase (Number)